miR‐186 can be delivered via anti‐CD56‐coated liposomal nanoparticles to target CD56 on NB cells or NK cells, thereby suppressing MYCN‐induced NB progression or preventing transforming growth factor beta 1 (TGFβ1)‐mediated NK cell inhibition, respectively, and optimising immunotherapy.61 The gene discussed is TGFB1; the disease is neuroblastoma.